PMID- 36942686
OWN - NLM
STAT- MEDLINE
DCOM- 20230328
LR  - 20230328
IS  - 1744-8301 (Electronic)
IS  - 1479-6694 (Linking)
VI  - 18
IP  - 40
DP  - 2022 Dec
TI  - Adverse events and clinical outcomes in patients treated with PD-(L)1 blockade 
      for advanced non-small-cell lung cancer.
PG  - 4509-4523
LID - 10.2217/fon-2022-1117 [doi]
AB  - Aims: To describe, in patients with advanced/metastatic non-small-cell lung 
      cancer, the relationship between baseline immunosuppressive drug 
      (ISD)/corticosteroid (CS) use, as well as the incidence of mild/moderate adverse 
      events (AEs), and the clinical effectiveness of PD (L)-1 blockade. Patients & 
      methods: This was a retrospective cohort study of patients with no evidence 
      (n = 131) or positive evidence (n = 269) of ISD/CS use. Results: Duration of 
      treatment, time to next treatment, progression-free survival and overall survival 
      were significantly reduced for patients with evidence of prior ISD/CS use. 
      Occurrence of mild/moderate AEs did not affect any clinical outcomes. Conclusion: 
      Prior ISD/CS use was associated with a poorer prognosis in advanced/metastatic 
      non-small-cell lung cancer patients treated with PD-(L)1 inhibitors, but the 
      occurrence of AEs had no effect.
FAU - Zhang, Yan
AU  - Zhang Y
AD  - Bristol Myers Squibb, 3401 Princeton Pike, Lawrence Township, NJ 08648, USA.
FAU - Doran, Charlotte
AU  - Doran C
AD  - ConcertAI, 6555 Quince, Suite 400, Memphis, TN 38119, USA.
FAU - Le, Trong Kim
AU  - Le TK
AD  - Bristol Myers Squibb, 3401 Princeton Pike, Lawrence Township, NJ 08648, USA.
FAU - Dreyfus, Brian
AU  - Dreyfus B
AUID- ORCID: 0000-0002-4241-9024
AD  - Bristol Myers Squibb, 3401 Princeton Pike, Lawrence Township, NJ 08648, USA.
FAU - Kola, Nina
AU  - Kola N
AD  - Bristol Myers Squibb, 3401 Princeton Pike, Lawrence Township, NJ 08648, USA.
FAU - Sylvester, Brooke E
AU  - Sylvester BE
AD  - Bristol Myers Squibb, 3401 Princeton Pike, Lawrence Township, NJ 08648, USA.
FAU - Lal, Lincy
AU  - Lal L
AD  - ConcertAI, 6555 Quince, Suite 400, Memphis, TN 38119, USA.
FAU - Penrod, John R
AU  - Penrod JR
AD  - Bristol Myers Squibb, 3401 Princeton Pike, Lawrence Township, NJ 08648, USA.
FAU - Meadows Shropshire, Stephanie
AU  - Meadows Shropshire S
AD  - Bristol Myers Squibb, 3401 Princeton Pike, Lawrence Township, NJ 08648, USA.
LA  - eng
GR  - Bristol-Myers Squibb/
PT  - Journal Article
DEP - 20230321
PL  - England
TA  - Future Oncol
JT  - Future oncology (London, England)
JID - 101256629
RN  - 0 (Immunosuppressive Agents)
SB  - IM
MH  - Humans
MH  - *Carcinoma, Non-Small-Cell Lung
MH  - *Lung Neoplasms/pathology
MH  - Retrospective Studies
MH  - Treatment Outcome
MH  - Immunosuppressive Agents/therapeutic use
OAB - What is the article about? Patients with advanced/metastatic non-small-cell lung 
      cancer (aNSCLC) are often treated with a class of drugs known as checkpoint 
      inhibitors. There have been previous reports that treatment with corticosteroids 
      and other drugs that suppress the immune system in the period leading up to 
      treatment with checkpoint inhibitors may result in poorer outcomes, but most of 
      these reports focus on serious adverse events leading to hospitalizations or 
      emergency room visits that result from treatment. This study aimed to determine 
      whether treatment with corticosteroids in these patients had any impact on the 
      occurrence of mild or moderate adverse events and long-term treatment outcomes. 
      What were the results? By looking back at deidentified medical insurance claims 
      from patients with aNSCLC, we found that patients who were treated with 
      corticosteroids or other immunosuppressive drugs (vs those who did not receive 
      these drugs) in the months leading up to treatment with checkpoint inhibitors had 
      poorer treatment outcomes (e.g., shorter overall survival). What do the results 
      of the study mean? This study investigated the real-world outcomes in aNSCLC 
      patients treated with checkpoint inhibitors and found that the use of 
      corticosteroids or other immunosuppressive drugs may have an adverse effect. 
      However, we are unable to rule out the possibility that there was an underlying 
      difference between these two sets of patients that caused the difference in 
      treatment outcomes. Further studies with larger sample sizes are needed.
OABL- eng
OTO - NOTNLM
OT  - PD-(L)1 blockade
OT  - carcinoma
OT  - electronic health records
OT  - immune checkpoint inhibitors
OT  - immunosuppressive drugs
OT  - non-small-cell lung cancer
OT  - retrospective studies
EDAT- 2023/03/22 06:00
MHDA- 2023/03/28 17:16
CRDT- 2023/03/21 06:03
PHST- 2023/03/28 17:16 [medline]
PHST- 2023/03/22 06:00 [pubmed]
PHST- 2023/03/21 06:03 [entrez]
AID - 10.2217/fon-2022-1117 [doi]
PST - ppublish
SO  - Future Oncol. 2022 Dec;18(40):4509-4523. doi: 10.2217/fon-2022-1117. Epub 2023 
      Mar 21.